Status:
UNKNOWN
Lucid Registry Study
Lead Sponsor:
Lucid Diagnostics, Inc.
Conditions:
Barrett Esophagus
Esophageal Adenocarcinoma
Eligibility:
All Genders
12+ years
Brief Summary
This is a multicenter, prospective, observational study designed to capture a limited set of data consisting of diagnostic test results and clinical management information on subjects who undergo EC/E...
Eligibility Criteria
Inclusion
- Males and Females who have provided informed consent for prospective registry participation
- Subject in whom the clinical decision has been made to screen for BE/EAC using EsoGuard testing on samples collected with EsoCheck
Exclusion
- Inability to provide written informed consent
- Subjects who fall outside the eligible population defined by the EsoCheck device Instructions For Use (IFU)
Key Trial Info
Start Date :
April 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05965999
Start Date
April 11 2023
End Date
June 1 2024
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LUCID DX
Lake Forest, California, United States, 92630